{"name":"Genervon Biopharmaceuticals, LLC","slug":"genervon-biopharmaceuticals-llc","ticker":"","exchange":"","domain":"","description":"Genervon Biopharmaceuticals, LLC is a biotechnology company focused on the discovery and development of novel treatments for neurodegenerative diseases. The company's pipeline includes three drugs in Phase 2 clinical trials, targeting conditions such as ALS and Alzheimer's disease.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"GM604","genericName":"GM604","slug":"gm604","indication":"Other","status":"phase_2"},{"name":"GM602","genericName":"GM602","slug":"gm602","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"GM604","genericName":"GM604","slug":"gm604","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GM602","genericName":"GM602","slug":"gm602","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPN0tvTFNCandpS0hmWG1mdjB0VWJ2djB4R1R3bFRDZk9IaEFoa3d1MmJQRkRjSDhuV21nTFh4Y2RwcWxFaU5aTEI0eFI2VDRUcnZTLXQ0cXJKRGUtLWxrRXRGUG1MOWh5aDVscWI4SkYzSy1HQWdlaHdQZUNiZEVYMkNqQWsyQnVpZHFpRWxldw?oc=5","date":"2025-04-17","type":"trial","source":"Market Data Forecast","summary":"Amyotrophic Lateral Sclerosis Market Size & Growth, 2033 - Market Data Forecast","headline":"Amyotrophic Lateral Sclerosis Market Size & Growth, 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxNSm1rNWlLNmo3OURRbkVFY1djc0paTWs3ajVWVkVxenhRbGtlQlFKT3NkeEpHSmVhU2IxRHU2aENMWUhoWUdFTHRyODRuQkU1RzBYN0NHMzkwdXFwVlZmVllUSmZ4eDZuTnR6WHpxUW9hS05RMzZteUF6eUtYUDRua0ItTWpNVTNDN3JGQzdNTVJfYndIaW1RMlVacWtoemhTNm9YXzdyVWdBd2gxMGNDampZb0ExQjljcFR2Uk92OTVtLWtKZU96RlE0RUUzaVVXM29xRlpEcW9idU1ac2FrbWN2M0dvYmhSS0ZNSjdyQ3lmaXZsVjgtcnBHTUZpRkphMGN0QkZhc3J5clg4WEtPN2VwOXlZckJEU0d2WHp6bnZWMkJUYi1uRkI3ZGJPY2tLenNDYTNHZmphVVdXT25JYXdsZElUVHR3Mi12c2VVNS0?oc=5","date":"2025-02-06","type":"pipeline","source":"GlobeNewswire","summary":"Drug Delivery Across Blood Brain Barrier (BBB) Market Eyes - GlobeNewswire","headline":"Drug Delivery Across Blood Brain Barrier (BBB) Market Eyes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPalFZbHRFVllMLUtMb09pb1VvYWtnWTNNLVRCQmFWWTFXZ2d6b0V3cjhhdnFRYVBVd25zclRSYUFJendSVkZmNXU1TEdKeTVuWmVTZzBadzVId25NODU3QzAxVGs0RnR4RVFrc2ZId3pObksxSVVCZGc1bFp4UF80NTd3?oc=5","date":"2019-08-18","type":"pipeline","source":"Market.us","summary":"Amyotrophic Lateral Sclerosis (ALS) Treatment Market - Market.us","headline":"Amyotrophic Lateral Sclerosis (ALS) Treatment Market","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}